Alder Biopharma

Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) hit a new 52-week low Wednesday for the second consecutive day as many investors found fault with the company's results from a phase 3 trial of its Eptinezumab therapy for the treatment of migraines. Piper Jaffray's Charles Duncan, Ph.D....

Last week's IPOs waited until Friday to debut: Ares Management (NYSE: ARES), Papa Murphy's (NASDAQ: FRSH), Aldeyra Therapeutics (NASDAQ: ALDX), and Scynexis (NASDAQ: SCYX). These IPOs enter a heavily mixed market as the S&P 500 swung between green and red after the employment situation...